Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma

J Am Coll Surg. 2020 Nov;231(5):554-556. doi: 10.1016/j.jamcollsurg.2020.08.751.
No abstract available

Publication types

  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Gene Expression Profiling
  • Humans
  • Melanoma* / therapy
  • Patient Selection
  • Skin Neoplasms* / therapy